Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: A case study of amiodarone

Drug Metabolism and Disposition

Volumn 43, Issue 2, 2015, Pages 182-189

  Chen, Yuan ^a   Mao, Jialin ^a   Hop, Cornelis E C A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEETHYLAMIODARONE; METOPROLOL; SIMVASTATIN; WARFARIN; ANTIARRHYTHMIC AGENT; CYTOCHROME P450 2C9 INHIBITOR; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A INHIBITOR; MONO-N-DESETHYLAMIODARONE;

AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG HALF LIFE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; PREDICTION; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; VOLUME OF DISTRIBUTION; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; CHEMISTRY; COMPUTER SIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; EXPERT SYSTEM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2C9 INHIBITORS; CYTOCHROME P-450 CYP2D6 INHIBITORS; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPERT SYSTEMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84919731574     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059311     Document Type: Article

References (36)

1. Andreasen F, Agerbaek H, Bjerregaard P, and Gøtzsche H (1981) Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 19:293-299.
2. Avdeef A, Box KJ, Comer JE, Hibbert C, and Tam KY (1998) pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res 15:209-215.
3. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, and Funck-Brentano C (2007) Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 81:679-684.
4. Bonati M, Galletti F, Volpi A, Cumetti C, Rumolo R, Bassini O, and Tognoni G (1983) Amiodarone in patients on long-term dialysis. N Engl J Med 308:906.
5. Callegari E, Kalgutkar AS, Leung L, Obach RS, Plowchalk DR, and Tse S (2013) Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047-2055.
6. Canada AT and Lesko LJ (1980) Two reasons for unusual therapeutic drug monitoring results in hospitalized patients. Ther Drug Monit 2:217-219.
7. Cao Y and Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711-723.
8. Halladay J.S., Wong S., Jaffer S.M., Sinhababu A.K., and Khojasteh-Bakht S.C. (2007). Metabolic stability screen for drug discovery using cassette analysis and column switching. Drug Metab Lett 1:67-72.
9. Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, and Goulart DA (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 51:398-407.
10. Holt DW, Tucker GT, Jackson PR, and Storey GC (1983) Amiodarone pharmacokinetics. Am Heart J 106:840-847.
11. Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298.
12. Jamei M, Dickinson GL, and Rostami-Hodjegan A (2009) A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53-75.
13. Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, and Singh BN (1982) Amiodarone kinetics after oral doses. Clin Pharmacol Ther 31:438-444.
14. Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, and Peters SA (2013) Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development. Drug Metab Dispos 41:2033-2046.
15. Lalloz MR, Byfield PG, Greenwood RM, and Himsworth RL (1984) Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J Pharm Pharmacol 36:366-372.
16. Latini R, Tognoni G, and Kates RE (1984) Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 9:136-156.
17. Marchiset D, Bruno R, Djiane P, Cano JP, Benichou M, and Serradimigni A (1985) Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm Drug Dispos 6:209-215.
18. McDonald MG, Au NT, Wittkowsky AK, and Rettie AE (2012) Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther 91:709-717.
19. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000a) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
20. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, and Yokoi T (2000b) Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244-253.
21. O'Reilly RA, Trager WF, Rettie AE, and Goulart DA (1987) Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 42: 290-294.
22. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, and Ogilvie BW (2011) An evaluation of the dilution method for identifying metabolismdependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370-1387.
23. Plomp TA, van Rossum JM, Robles de Medina EO, van Lier T, and Maes RA (1984) Pharmacokinetics and body distribution of amiodarone in man. Arzneimittelforschung 34:513-520.
24. Riva E, Gerna M, Latini R, Giani P, Volpi A, and Maggioni A (1982) Pharmacokinetics of amiodarone in man. J Cardiovasc Pharmacol 4:264-269.
25. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
26. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
27. Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, and Isoherranen N (2014) Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 95:653-662.
28. Smith D.A., and Dalvie D. (2012). Why do metabolites circulate? Xenobiotica 42:107-126.
29. Sodhi JK, Ford KA, Mukadam S, Wong S, Hop CE, Khojasteh SC, and Halladay JS (2014) 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. Drug Metab Dispos 42:813-817.
30. Stäubli M, Troendle A, Schmid B, Balmer P, Kohler B, Studer H, and Bircher J (1985) Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. Eur J Clin Pharmacol 29:417-423.
31. Veronese ME, McLean S, and Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. Br J Clin Pharmacol 26:721-731.
32. Waters NJ, Jones R, Williams G, and Sohal B (2008) Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97:4586-4595.
33. Weiss M (1999) The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J Pharmacokinet Biopharm 27:383-396.
34. Werner D, Wuttke H, Fromm MF, Schaefer S, Eschenhagen T, Brune K, Daniel WG, and Werner U (2004) Effect of amiodarone on the plasma levels of metoprolol. Am J Cardiol 94: 1319-1321.
35. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
36. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.